Dr. Neelam Desai
Claim this profileLevine Cancer Institute
Studies Breast Cancer
Studies Breast cancer
6 reported clinical trials
13 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
HER2 negative
ER positive
2Breast Cancer
HER2 positive
HER2 negative
ER negative
Affiliated Hospitals
Clinical Trials Neelam Desai is currently running
CDK4/6 Inhibitors
for Metastatic Breast Cancer
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 65 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors. Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing). Note: Telehealth visits are allowed at any time per institutional guidelines. In addition, the study allows for remote consenting per institutional guidelines.
Recruiting2 awards Phase 33 criteria
Sacituzumab Govitecan + Pembrolizumab
for Breast Cancer
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
Recruiting2 awards Phase 211 criteria
More about Neelam Desai
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Neelam Desai has experience with
- Pertuzumab
- Trastuzumab
- Pembrolizumab
- Sacituzumab Govitecan
- ADJUVANT ENDOCRINE THERAPY
- Palbociclib
Breakdown of trials Neelam Desai has run
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Neelam Desai specialize in?
Neelam Desai focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are HER2 negative.
Is Neelam Desai currently recruiting for clinical trials?
Yes, Neelam Desai is currently recruiting for 3 clinical trials in Albemarle North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Neelam Desai has studied deeply?
Yes, Neelam Desai has studied treatments such as Pertuzumab, Trastuzumab, Pembrolizumab.
What is the best way to schedule an appointment with Neelam Desai?
Apply for one of the trials that Neelam Desai is conducting.
What is the office address of Neelam Desai?
The office of Neelam Desai is located at: Levine Cancer Institute, Albemarle, North Carolina 28001 United States. This is the address for their practice at the Levine Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.